Prediction Case File
YouTubeTracking Live

The Stock Market Just Hit a Critical Turning Point: MU, SNDK, MRVL Analysis

11 extracted signals · 0 resolved · 11 still active

Bullseye Stocks profile imageBullseye StocksIndependent analyst profile
Source published
22 Nov 2026, 18:14 UTC
Recorded by Tahlil Plus
22 Nov 2026, 20:16 UTC
Video preview for The Stock Market Just Hit a Critical Turning Point: MU, SNDK, MRVL Analysis
Source overview

AI-generated source summary

The speaker provides technical analysis across various tech stocks and ETFs experiencing severe pullbacks and approaching key support and liquidity zones. Using momentum indicators, price meters, and historical volume data, the analysis highlights potential trend reversals and bounce levels, emphasizing disciplined risk management during market downturns.

AI-generated summary based on the source content.

Live evaluation

Signal outcomes at a glance

Tracking Live
Signals
11
Extracted from this source
Open
11
Still being tracked
Successful
0
Resolved successfully
Failed
0
Resolved unsuccessfully
Other
0
Cancelled, invalid or excluded
Resolved success
—
0 resolved; open signals omitted
Extracted intelligence

Signals in this source

Case timeline

Evidence and evaluation progress

  1. Original source published

    The analyst published the original source item.

  2. Source recorded by Tahlil Plus

    The public source was preserved as the evidence record for this case.

  3. Market predictions extracted

    11 eligible signals linked to this case.

  4. Source processing completed

    Source analysis and structured extraction completed.

  5. Live evaluation in progress

    11 signals remain active.

Analyst snapshot

Bullseye Stocks

Platform-wide history, separate from this source evaluation.

Reliability
43.0
Tracked signals
53
Historical success
32.0%
View full analyst profile →
Methodology & disclosure

Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.

Continue the evidence trail